Cargando…
European principles of inhibitor management in patients with haemophilia
BACKGROUND: In spite of recent major advances in the understanding and treatment of inhibitor development in patients with haemophilia, multidisciplinary management of many of these patients remains suboptimal and highly heterogenous across Europe. METHODS: Following a series of multidisciplinary me...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5921290/ https://www.ncbi.nlm.nih.gov/pubmed/29703220 http://dx.doi.org/10.1186/s13023-018-0800-z |
_version_ | 1783317976821268480 |
---|---|
author | Giangrande, P. L. F. Hermans, C. O’Mahony, B. de Kleijn, P. Bedford, M. Batorova, A. Blatný, J. Jansone, K. |
author_facet | Giangrande, P. L. F. Hermans, C. O’Mahony, B. de Kleijn, P. Bedford, M. Batorova, A. Blatný, J. Jansone, K. |
author_sort | Giangrande, P. L. F. |
collection | PubMed |
description | BACKGROUND: In spite of recent major advances in the understanding and treatment of inhibitor development in patients with haemophilia, multidisciplinary management of many of these patients remains suboptimal and highly heterogenous across Europe. METHODS: Following a series of multidisciplinary meetings and a review of the literature, the European haemophilia community of health professionals and patients jointly defined practical optimum standards for ensuring and harmonizing treatment and care for patients with an inhibitor. RESULTS: Ten complementary principles for the management of inhibitors in haemophilia have been developed, emphasizing the importance and benefits of a centralized, multidisciplinary, expert and holistic approach. CONCLUSIONS: This document will serve as a benchmark to improve the multidisciplinary and practical management of patients with inhibitor. Implementation and adherence to each of these principles should have a major positive impact on the management and outcomes of patients developing an inhibitor. |
format | Online Article Text |
id | pubmed-5921290 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-59212902018-05-01 European principles of inhibitor management in patients with haemophilia Giangrande, P. L. F. Hermans, C. O’Mahony, B. de Kleijn, P. Bedford, M. Batorova, A. Blatný, J. Jansone, K. Orphanet J Rare Dis Position Statement BACKGROUND: In spite of recent major advances in the understanding and treatment of inhibitor development in patients with haemophilia, multidisciplinary management of many of these patients remains suboptimal and highly heterogenous across Europe. METHODS: Following a series of multidisciplinary meetings and a review of the literature, the European haemophilia community of health professionals and patients jointly defined practical optimum standards for ensuring and harmonizing treatment and care for patients with an inhibitor. RESULTS: Ten complementary principles for the management of inhibitors in haemophilia have been developed, emphasizing the importance and benefits of a centralized, multidisciplinary, expert and holistic approach. CONCLUSIONS: This document will serve as a benchmark to improve the multidisciplinary and practical management of patients with inhibitor. Implementation and adherence to each of these principles should have a major positive impact on the management and outcomes of patients developing an inhibitor. BioMed Central 2018-04-27 /pmc/articles/PMC5921290/ /pubmed/29703220 http://dx.doi.org/10.1186/s13023-018-0800-z Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Position Statement Giangrande, P. L. F. Hermans, C. O’Mahony, B. de Kleijn, P. Bedford, M. Batorova, A. Blatný, J. Jansone, K. European principles of inhibitor management in patients with haemophilia |
title | European principles of inhibitor management in patients with haemophilia |
title_full | European principles of inhibitor management in patients with haemophilia |
title_fullStr | European principles of inhibitor management in patients with haemophilia |
title_full_unstemmed | European principles of inhibitor management in patients with haemophilia |
title_short | European principles of inhibitor management in patients with haemophilia |
title_sort | european principles of inhibitor management in patients with haemophilia |
topic | Position Statement |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5921290/ https://www.ncbi.nlm.nih.gov/pubmed/29703220 http://dx.doi.org/10.1186/s13023-018-0800-z |
work_keys_str_mv | AT giangrandeplf europeanprinciplesofinhibitormanagementinpatientswithhaemophilia AT hermansc europeanprinciplesofinhibitormanagementinpatientswithhaemophilia AT omahonyb europeanprinciplesofinhibitormanagementinpatientswithhaemophilia AT dekleijnp europeanprinciplesofinhibitormanagementinpatientswithhaemophilia AT bedfordm europeanprinciplesofinhibitormanagementinpatientswithhaemophilia AT batorovaa europeanprinciplesofinhibitormanagementinpatientswithhaemophilia AT blatnyj europeanprinciplesofinhibitormanagementinpatientswithhaemophilia AT jansonek europeanprinciplesofinhibitormanagementinpatientswithhaemophilia AT europeanprinciplesofinhibitormanagementinpatientswithhaemophilia |